Absolute Antibody

We’re thrilled to merge with Vector Laboratories! This partnership will enhance our offerings and drive innovation in antibody solutions for the life sciences community. Stay tuned for more updates.

Visit us at PEGS Boston! Stop by booth #400 to meet with our experts and discover how our custom services and catalog solutions can benefit your research. Catherine Bladen PhD, Micayla Bowman, PhD, Michael Fiebig, and Jason Shields will be on site. See you there!

Need expert antibody services? We got you covered! 🧬 Sequencing – From hybridomas or purified proteins ⚙️ Engineering – Reformatting, humanization & bispecifics 🧪 Expression – Recombinant production at any scale High-quality, tailored antibodies for your research.

This 2024 study used Absolute Antibody's anti-TIGIT 1B4 to find that combination therapy targeting TIGIT and Tregs was effective at slowing ovarian cancer, the deadliest gynecological cancer. Full study: tinyurl.com/5efe7vsr

In a recent paper, Absolute Antibody’s Prometheus™ service was utilized to humanize a hybridoma-derived LGR5 antibody. The humanized variants were then used to develop bispecific t-cell engagers and antibody drug conjugates for further testing. tinyurl.com/4vdahn3z

Metapneumovirus cases are surging in China. To aid research, we engineered multiple anti-MPV antibody clones in a variety of formats for diverse applications. Full list: bit.ly/3WlqIGy

From wild cats to house pets, the H5N1 Bird Flu is spreading. In WA, a sanctuary lost 20 big cats, and a house cat in OR died after eating raw food. To help research, we’ve engineered Cat IgG1 & IgM anti-H5N1 antibodies for diagnostics. Browse our catalog: bit.ly/3DnntaG

Transform your antibodies for clinical use with Prometheus™. Receive 10% off our in silico humanization service until the end of the year. Contact us for a quote: tinyurl.com/8wd9mt4s

Antimicrobial resistance is on the rise and is estimated to reach $1 trillion USD in additional healthcare costs by the year 2050. One solution being explored for this public health crisis is the use of antibodies as antibacterial agents. Learn more: tinyurl.com/ykrbwkn6

Our new article highlights the mechanisms of antibody-mediated cell depletion and how it revolutionizes cancer and autoimmune disease treatment. Read the article here: absoluteantibody.com/general/therap… #AntibodyTherapeutics

Our team, Catherine Bladen PhD and Alex Scott, will be at #PEGSEurope next week in Barcelona, Spain. We invite you to visit us at booth #1310 to learn more about our custom services and explore our extensive antibody reagent catalog.

Absolute Antibody is excited to announce that we have joined the PACE Delivery Partner Network to offer our recombinant antibody expertise to researchers studying antimicrobial resistance. Learn more here: shorturl.at/UuptO

DON’T MISS OUT: Join Absolute Antibody and Dr. Lucia Lupica Spagnolo tomorrow as we discuss the process of humanizing antibodies from murine and non-murine origins. Register here: bit.ly/3XOOls5

Join us Oct. 2 for a live webinar with Dr. Lucia Lupica-Spagnolo as she discusses the Prometheus 2.0™ antibody humanization platform and how it has been optimized to increase expression titers and decrease aggregation of humanized antibodies: bit.ly/3XOOls5

A new mAb has entered human clinical trials targeting Nipah, a virus passed from bats to humans that kills up to 75% of infected people. Recombinant anti-Nipah mAbs: ow.ly/wMvC50Tm2xH More info: ow.ly/iimM50Tm2xI

Our Chief Scientific Officer Michael Fiebig will be speaking at an online workshop hosted by the @PCRM on Sept. 11th. Learn more: ow.ly/z9xk50Tk94A

A new study uses our recombinant anti-DNA-RNA hybrid antibodies to shed light on the roles ATRX/DAXX plays in genomic stability and even cancer. This and more in our article: ow.ly/ZCSy50Tfkut

Our new article reviews how blocking antibodies are used as cancer therapeutics and how antibody engineering enables even more research possibilities. Article link: ow.ly/NXvv50T8Kho

An excellent overview of Fc "silencing" methods used in clinical antibodies. It is clear that many approaches still retain Fc-mediated activity - especially those in the LALA-family. Contact us if you want to work with the truly silent STR-platform for silencing human IgG1.

Mpox has been declared a public health emergency. Recombinant engineered antibodies can help develop better vaccines and diagnostics. #Mpox Read more here: absoluteantibody.com/general/2024-m…

New Case Study: Engineering Chimeric Antibodies to Study IgG Hexamerization. Researchers at UCSF used antibody engineering to determine that assembly of IgG alloantibody multimers is a critical event initiating complement-dependent lung injury responses. ow.ly/zWY850SYXUr